Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Destroy Cancer Cells Equipment Supplied In Europe
10 equipment items found
Manufactured by:Oxford Vacmedix UK Limited based inOxford, UNITED KINGDOM
In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T Cells that will recognise the same marker on cancer cells leading to their destruction. ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical areas for diagnosis and/or therapy. Targeted radiopharmaceuticals bind to specific structures such as proteins or cells within the body and thus accumulate in particular places, such as e.g. tumor lesions in a cancer ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:OncoVITA based inParis, FRANCE
Oncovita’s MeasovirTM proprietary platform relies on a DNA plasmid vector that expresses a modified measles Schwarz virus antigenome able to generate recombinant viruses by using a clonal reverse genetics system. This versatile plug-and-play platform allows producing new viruses expressing very large amounts of additional genetic ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
The company´s proprietary platform technology is based on the discovery of a novel tumor-specific marker - a membrane-expressed form of heat shock protein 70 (Hsp70). Membrane Hsp70 is most frequently expressed on a variety of different tumor types including lung, colon, breast, head and neck, stomach, pancreas carcinomas, malignant melanoma, and hematological diseases, but never on the ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies. The video below provides more ...
by:Pure Biologics SA based inWroclaw, POLAND
Triple-negative breast cancer (TNBC) is a highly proliferative, rapidly growing, and aggressive form of cancer. TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor microenvironment; Type 2 is characterized by inactive cells of the innate immune system; Type 3 (also ...